Logo image of ONCO

ONCONETIX INC (ONCO) Stock Fundamental Analysis

NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD

0.635  -0.01 (-0.78%)

Fundamental Rating

0

Taking everything into account, ONCO scores 0 out of 10 in our fundamental rating. ONCO was compared to 572 industry peers in the Biotechnology industry. ONCO may be in some trouble as it scores bad on both profitability and health. ONCO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ONCO had negative earnings in the past year.
ONCO had a negative operating cash flow in the past year.
ONCO had negative earnings in each of the past 5 years.
ONCO had a negative operating cash flow in each of the past 5 years.
ONCO Yearly Net Income VS EBIT VS OCF VS FCFONCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -83.34%, ONCO is not doing good in the industry: 69.91% of the companies in the same industry are doing better.
ONCO has a Return On Equity of -152.17%. This is in the lower half of the industry: ONCO underperforms 64.42% of its industry peers.
Industry RankSector Rank
ROA -83.34%
ROE -152.17%
ROIC N/A
ROA(3y)-75.1%
ROA(5y)-57.66%
ROE(3y)-134.27%
ROE(5y)-93.36%
ROIC(3y)N/A
ROIC(5y)N/A
ONCO Yearly ROA, ROE, ROICONCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONCO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCO Yearly Profit, Operating, Gross MarginsONCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

1

2. Health

2.1 Basic Checks

ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ONCO has been reduced compared to 1 year ago.
Compared to 1 year ago, ONCO has a worse debt to assets ratio.
ONCO Yearly Shares OutstandingONCO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M
ONCO Yearly Total Debt VS Total AssetsONCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

ONCO has an Altman-Z score of -2.95. This is a bad value and indicates that ONCO is not financially healthy and even has some risk of bankruptcy.
ONCO has a Altman-Z score of -2.95. This is comparable to the rest of the industry: ONCO outperforms 47.43% of its industry peers.
A Debt/Equity ratio of 0.29 indicates that ONCO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.29, ONCO is doing worse than 71.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -2.95
ROIC/WACCN/A
WACC9.81%
ONCO Yearly LT Debt VS Equity VS FCFONCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

ONCO has a Current Ratio of 0.06. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCO's Current ratio of 0.06 is on the low side compared to the rest of the industry. ONCO is outperformed by 99.12% of its industry peers.
ONCO has a Quick Ratio of 0.06. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCO's Quick ratio of 0.05 is on the low side compared to the rest of the industry. ONCO is outperformed by 99.12% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.05
ONCO Yearly Current Assets VS Current LiabilitesONCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ONCO have decreased strongly by -8438.23% in the last year.
EPS 1Y (TTM)-8438.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-845.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ONCO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -14.13% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.84%
EPS Next 2Y-14.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCO Yearly Revenue VS EstimatesONCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 10K 20K 30K 40K 50K
ONCO Yearly EPS VS EstimatesONCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ONCO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ONCO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCO Price Earnings VS Forward Price EarningsONCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCO Per share dataONCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

A cheap valuation may be justified as ONCO's earnings are expected to decrease with -14.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.13%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ONCO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ONCONETIX INC

NASDAQ:ONCO (2/5/2025, 11:40:29 AM)

0.635

-0.01 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2024-05-12
Earnings (Next)N/A N/A
Inst Owners1.26%
Inst Owner Change-0.02%
Ins Owners11.45%
Ins Owner Change23.36%
Market Cap5.26M
Analysts43.33
Price TargetN/A
Short Float %4.39%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.81
P/FCF N/A
P/OCF N/A
P/B 0.16
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-95.63
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0.23
BVpS4.09
TBVpS-3.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -83.34%
ROE -152.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.1%
ROA(5y)-57.66%
ROE(3y)-134.27%
ROE(5y)-93.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.48%
Cap/Sales 1.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.05
Altman-Z -2.95
F-Score3
WACC9.81%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8438.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-845.26%
EPS Next Y-11.84%
EPS Next 2Y-14.13%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-111.4%
OCF growth 3YN/A
OCF growth 5YN/A